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Abstract
Invasive infections with methicillin-resistant Staphylococcus aureus (MRSA) have been associated with increased morbidity and mortality. The
aim of the present study was to identify independent predictors of early mortality and treatment failure in patients with MRSA bacteraemia.
A total of 132 adult patients who developed MRSA bacteraemia during hospitalization in the University Hospital of Vienna between 2000
and 2011 were screened and 124 were included in a retrospective cohort study. Patient demographics, source of bacteraemia, antimicrobial
treatment and microbiological characteristics were evaluated. The 28-day crude mortality was 30.6%. Predictors of early mortality identified
in multivariate Cox regression analysis included higher patient age (adjusted hazard ratio (aHR) 1.03, 95% CI 1.01–1.06, p 0.006), pneumonia
(aHR 3.86, 95% CI 1.83–8.12, p <0.001) and failure to use MRSA active treatment (aHR 8.77, 95% CI 3.50–21.93, p <0.001). Ninety-one
(73.4%) patients received glycopeptides as specific MRSA treatment. Of 63 patients treated with vancomycin, only 14 (22.6%) patients had
aimed trough levels of 15–20 mg/L. Vancomycin MIC  2 mg/L was detected in 28.2% and was associated with glycopeptide pretreatment
(p 0.001). All MRSA isolates were susceptible to linezolid and tigecycline. Persistent bacteraemia  7 days was documented in 25 (20.2%)
patients. Independent determinants for microbiological eradication failure in patients with MRSA bacteraemia included endocarditis
(p <0.001) and vancomycin trough levels (p 0.014), but not vancomycin MIC. Failure of clinical and microbiological eradication of MRSA
among patients with MRSA bacteraemia was associated with clinical entity rather than with bacterial traits. Pharmacokinetic parameters
seem to be decisive on microbiological and clinical success.
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Introduction
Invasive infections with methicillin-resistant Staphylococcus
aureus (MRSA) have been associated with greater morbidity
and mortality than infections with methicillin-susceptible
strains as the result of a combination of host-, pathogen- and
therapy-related factors [1,2]. In Austria the proportion of
invasive S. aureus isolates resistant to methicillin is low at 5–
10% compared with high resistance rates of 25–50% in
southern Europe and 43.2% in the USA [3,4]. Standard
practice in Austria, therefore, does not normally include
MRSA antimicrobials in the empirical treatment of critically ill
patients.
A number of therapy-unrelated parameters associated with
poor clinical outcome have been identified: these include
higher patient age, underlying comorbidities such as liver
cirrhosis, the site of MRSA infection and the need for early
intensive care unit admission [5,6]. Nevertheless, modified
MRSA-specific treatments may improve clinical outcomes. In
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the past decade, the glycopeptide vancomycin was the
antimicrobial of choice for serious MRSA infections such as
bacteraemia, endocarditis, pneumonia and osteomyelitis.
Reduced susceptibility to glycopeptides is an emerging prob-
lem however, and even borderline-high vancomycin MIC of
2 mg/L and low vancomycin trough levels are associated with
MRSA treatment failure [7–9]. As alternatives to vancomycin,
newer MRSA-active antibiotics such as the oxazolidinone
linezolid, the glycylcycline tigecycline and the cyclic lipopeptide
daptomycin have been introduced into clinical practice [10].
The aim of the present study in patients with MRSA
bacteraemia was to determine clinical and microbiological
outcomes and to identify independent predictors of treatment
failure in a region with low MRSA prevalence.
Patients and Methods
Study design and study population
This retrospective cohort study took place in the University
Hospital of Vienna, Austria, a 2141-bed central hospital with a
large transplant centre for solid organ transplantation, a
haematology–oncology unit that includes a bone marrow
transplant unit, and a large intensive care, emergency medicine
and surgery unit. After approval by the local ethics committee
in 2012 (No. 1469/2012), we screened retrospectively for adult
patients with MRSA bacteraemia hospitalized in the University
Hospital between January 2000 and September 2011. Only the
first episode of MRSA bacteraemia in each patient was included.
Patients were excluded if their medical records or microbio-
logical culture for MRSA were not available.
Demographic characteristics obtained from patients’ med-
ical records included age, sex, recent major surgery, underlying
diseases, comorbidities, source of MRSA bacteraemia (e.g.
central venous catheter-related, skin or soft tissue infection,
pneumonia, mediastinitis, peritonitis, infective endocarditis),
antimicrobial treatment data (type, number of antimicrobials),
additional surgical intervention, admittance to intensive care
unit, and response to treatment (clinical and microbiological
response). Treatment failure was defined as any of the
following: 28-day mortality, persistent MRSA bacteraemia
lasting  7 days or persistent signs and symptoms of infection
at the end of antimicrobial therapy. Death was considered to
be related to MRSA bacteraemia if one of the following three
criteria was present: MRSA-positive blood cultures at the time
of death, death occurring before resolution of the signs and
symptoms of MRSA bacteraemia, or autopsy finding indicated
MRSA infection as a cause of death.
Wherever available from laboratory data, initial vancomycin
or teicoplanin trough levels at steady state (immediately before
the fourth dose) were evaluated for each patient who received
glycopeptides intravenously, because low glycopeptide trough
levels might be an important risk factor for treatment failure
[11].
Patients’ long-term outcomes (survival or death) 1 year
after MRSA bacteraemia were obtained from medical records
or from the local central bureau of statistics in Vienna.
Microbiological data
During the study period, relevant MRSA isolates were
cryopreserved for later antimicrobial susceptibility testing.
The first MRSA organism isolated from the patient’s blood-
stream was used for microbiological assessment. To determine
in vitro susceptibility, MIC of vancomycin, linezolid, tigecycline
and fosfomycin were measured in duplicate for each MRSA
bloodstream isolate using a broth microdilution method with
freshly prepared cation-adjusted M€uller–Hinton broth and an
inoculum of 5 9 105 CFU/mL, according to the guidelines of
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [12]. According to EUCAST clinical break-
points isolates were classified as resistant as follows: MIC for
vancomycin >2 mg/L, linezolid >4 mg/L, tigecycline >0.5 mg/L
and fosfomycin >32 mg/L [13]. Reduced susceptibility of
vancomycin was defined as an MIC of 2 mg/L as previously
described [8,9].
Statistical analysis
To interpret in vitro susceptibility results, the MIC50 and MIC90
of vancomycin, linezolid, tigecycline and fosfomycin were
calculated, together with the percentage of resistant isolates.
Differences in patients’ demographic data, underlying diseases,
comorbidities, source of MRSA bacteraemia, antimicrobial
treatment and microbiological data between groups with and
without survival at day 28 after positive blood culture for
MRSA, were compared between groups with and without
persistent bacteraemia  7 days, and between groups with and
without (clinical and microbiological) treatment failure. Cate-
gorical variables were expressed as frequencies and percentage
of the group from which they were derived. For continuous
variables, values were expressed as median (range). To explore
predictors of early mortality until day 28 after positive blood
culture with MRSA, univariate and multivariate Cox-regression
analyses were performed. All variables with a p-value <0.1 in
the univariate analysis were included in the multivariate Cox
regression model. Interactions between variables were
assessed and no relationships were detected (p >0.05) except
for age and solid organ transplantation with a low correlation
(r = 0.237, p 0.008). Adjusted hazard ratios (aHR) with 95%
CI were calculated. A two-tailed p-value <0.05 was considered
to be significant. To identify independent risk factors for
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persistent bacteraemia  7 days or treatment failure, logistic
regression analyses were performed. All variables associated
with either persistent bacteraemia  7 days or treatment
failure with a p-value <0.1 in the univariate analysis were used
to perform multivariate logistic regression analysis. To calculate
a binary logistic regression model, variables were standardized
and the constant was excluded. A stepwise backward method
was used to calculate a model for predicting persistent
bacteraemia  7 days or treatment failure. For the multivariate
model a two-tailed p-value <0.05 was considered to be
significant. SPSS version 20.0 for Windows (SPSS Inc., Chicago,
IL, USA) was used for all data analysis.
Results
Characterization of the study patients
A total of 132 patients with MRSA bacteraemia were screened
(Fig. 1). Eight patients were non-evaluable, leaving 124 patients
(98 men, 26 women) in the final analysis. The median age of
patients was 64.5 years (range 18–96 years). Seventy (56.5%)
patients had undergone recent major surgery. Median length of
hospital stay was 37 days (range 1–203 days); intensive care
unit admission was required in 46 (37.1%) patients. Fifty
(40.3%) patients died during hospitalization. The underlying
diseases included malignant haematological and solid organ
neoplasms (n = 36), end-stage kidney disease (n = 19), solid
organ transplantation (n = 14), alcoholic liver cirrhosis
(n = 14), severe peripheral vascular disease (n = 11), major
bleeding (n = 9), polytrauma (n = 7), burn (n = 5), inflamma-
tory bowel disease (n = 3), paraplegia (n = 2), vasculitis
(n = 2), pancreatitis (n = 1) and combined human immunode-
ficiency virus/hepatitis B virus/hepatitis C virus infection
(n = 1). Common comorbidities were diabetes mellitus
(n = 27), coronary artery disease (n = 23) and chronic
obstructive pulmonary disease (n = 17).
Sources of MRSA bacteraemia
Sources of infection were identified as follows: central venous
catheter-related MRSA bacteraemia in 37 (29.8%) patients,
pneumonia in 17 (13.7%) patients, infective endocarditis in 11
(8.9%) patients, skin and soft tissue infection in 5 (4%) patients,
peritonitis in 4 (3.2%) patients, foreign body infection and
mediastinitis each in 3 (2.4%) patients, and wound infection in 2
(1.6%) patients.
Trends of main study parameters
Trends of MRSA bacteraemia incidence, source of infection,
rate of death, microbiological persistence and vancomycin
trough levels through the study time comparing the time
periods 2000–2006 with 2007–2011 are shown in Table 1. A
significantly higher number of patients was included in the first
study period (85 versus 39 patients), but there was no trend
for the other study parameters.
Treatment regimens and glycopeptide trough levels
As initial antimicrobial therapy, 91 (73.4%) patients received
glycopeptides for  72 h: vancomycin monotherapy in 48
FIG. 1. Organogram of the study protocol, 28-day mortality and long-term outcome 1 year after methicillin-resistant Staphylococcus aureus (MRSA)
bacteraemia.
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cases, vancomycin combination therapy with either an amino-
glycoside or fosfomycin in 15 cases, teicoplanin monotherapy
in 23 cases, and teicoplanin combination therapy with either an
aminoglycoside, fosfomycin or linezolid in five cases. Vanco-
mycin trough levels at steady state varied greatly between
patients, with a median of 10 mg/L and total range 2.6–
45.8 mg/L. Only 14 (22.6%) patients had sufficiently high
trough levels of 15–20 mg/L. Median teicoplanin trough levels
at steady state were 39 mg/L, range 13.2–147 mg/L. Linezolid
and tigecycline were prescribed as initial treatment in seven
and two patients, respectively. Daptomycin was used in
combination with fosfomycin in a single patient. Fosfomycin,
aminoglycosides or rifampicin were administered as combina-
tion partners in 15, 16 and two patients, respectively. Fusidic
acid, cotrimoxazole and clindamycin were used in a total of
seven patients. Twenty-eight (22.6%) patients underwent
additional surgical intervention for source control. Six patients
received no MRSA-active treatment and all died. Antimicrobial
combination therapy was used in 30 (24.2%) patients. Persis-
tent bacteraemia  7 days was less common in patients with
combination therapy (3/25 (12%) patients versus 27/99 (27.3%)
patients), but no statistical significance was reached (p 0.13).
In vitro activity of vancomycin, linezolid, tigecycline and
fosfomycin against clinical MRSA bloodstream isolates of
patients with bacteraemia
Respective MIC50 and MIC90 values were 1 mg/L and 2 mg/L
for vancomycin, 2 mg/L and 2 mg/L for linezolid, 0.25 mg/L
and 0.5 mg/L for tigecycline, 4 mg/L and 16 mg/L for fosfo-
mycin (Table 2). All isolates were susceptible to linezolid and
tigecycline and five (4%) were resistant to fosfomycin.
Resistance to vancomycin (MIC >2 mg/L) was detected in
0.8%, reduced susceptibility to vancomycin (MIC = 2 mg/L)
was found in 27.4% of MRSA bloodstream isolates.
Association between glycopeptide pretreatment and
vancomycin MIC
Of 124 patients, 27 (21.8%) had previously received antibiotic
pretreatment with a glycopeptide intravenously. MRSA blood-
stream isolates of these pretreated patients had significantly
higher MIC of vancomycin (p 0.001): 3 of 19 patients,
vancomycin MIC 0.5 mg/L; 10 of 70 patients, vancomycin
MIC 1 mg/L; 13 of 34 patients, MIC of 2 mg/L; and one of one
patient, MIC 4 mg/L.
Clinical and microbiological treatment failure
The 28-day mortality in the study population was 30.6% and
death could be related to MRSA bacteraemia in 23.4%. The
crude mortality rate increased to 41.9% in the first half-year
after MRSA bacteraemia and reached 45.2% after the first year
(Fig. 1). Increasing age, solid organ transplantation, pneumonia
and failure to use an antimicrobial active against MRSA showed
significant influence on early mortality within the first 28 days
in the univariate Cox regression analyses (p <0.1). Looking at a
multivariate model including those four risk factors, only three
parameters remained statistically significant: higher patient age
(aHR 1.03, 95% CI 1.01–1.06, p 0.006), pneumonia as site of
infection (aHR 3.86, 95% CI 1.83–8.12, p <0.001) and failure to
use an MRSA-active antimicrobial substance (aHR 8.75, 95% CI
3.50–21.88, p <0.001). Differences between the Kaplan–Meier
survival curves of patients with and without pneumonia after a
follow up of 1 year are shown in Fig. 2. Among patients with
MRSA bacteraemia, 64.7% of those with pneumonia and 42.1%
of those without pneumonia had died at the end of the follow-
up period of 1 year.
Twenty-five (20.2%) patients developed persistent MRSA
bacteraemia  7 days. Two positive predictors for microbio-
logical eradication failure (p <0.1) were identified in the
univariate analyses: endocarditis and vancomycin monothera-
py. As negative predictors (p <0.1), persistent bacteraemia
was detected significantly less often in patients with central
venous catheter-related bacteraemia and in patients with high
TABLE 1. Trends in methicillin-resistant Staphylococcus aur-
eus (MRSA) bacteraemia incidence, source of infection, rate
of death, rate of patients with persistent bacteraemia
 7 days and vancomycin trough levels over the study
periods 2000–2006 and 2007–2011
Main study parameters
Time period
2000–2006
Time period
2007–2011
MRSA bacteraemia, no. of patients (%) 85 (68.5%) 39 (31.5%)
Source of infection
Infective endocarditis, no. of patients (%) 6 (7.1%) 5 (12.8%)
Pneumonia, no. of patients (%) 10 (11.8%) 7 (17.9%)
Central venous catheter-related, no. of
patients (%)
23 (27.1%) 14 (35.9%)
Others, no. of patients (%) 46 (54.1%) 13 (33.3%)
28-day mortality, no. of patients (%) 25 (29.4%) 13 (33.3%)
Hospital mortality, no. of patients (%) 35 (41.2%) 15 (38.5%)
Persistent bacteraemia  7 days, no. of
patients (%)
16 (18.8%) 9 (23.1%)
Vancomycin trough levels, median
(range) in mg/L
15.2 (2.6–45.8) 14.2 (5–25.5)
TABLE 2. In vitro antimicrobial activity of vancomycin,
linezolid, tigecycline and fosfomycin against 124 clinical
bloodstream isolates of methicillin-resistant Staphylococcus
aureus
Antimicrobial agent
MIC (mg/L)
S (%) R (%)MIC50 MIC90 Range
Vancomycin 1 2 0.5–4 99.2 0.8
Linezolid 2 2 1–2 100 0
Tigecycline 0.25 0.5 0.25–0.5 100 0
Fosfomycin 4 16 0.125–>256 96.0 4.0
MIC, minimal inhibitory concentration; S (%), percentage of susceptible isolates; R
(%), percentage of resistant isolates.
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vancomycin trough levels. However, in multivariate analysis
only endocarditis (p <0.001, adjusted odds ratio 2440.27) and
vancomycin trough levels (p 0.014, adjusted odds ratio 0.156)
remained statistically significant parameters provoking or
reducing persistent bacteraemia. Treatment failure was
observed in a total of 50 (40.3%) patients. Factors associated
with treatment failure among patients with MRSA bacteraemia
in the univariate analysis (p <0.1) are shown in Table 3.
Multivariate analysis showed only the following independent
risk factors to be significantly associated with treatment failure:
endocarditis (p 0.027, adjusted odds ratio 13.3) as positive
predictor and vancomycin trough levels (p 0.016, adjusted
odds ratio 0.29) as negative predictor. Pneumonia remained as
a risk factor in the multivariate model, but did not reach
statistical significance (p >0.05).
Discussion
Management of MRSA bacteraemia remains a substantial
challenge. In the present retrospective cohort study we
detected high 28-day and 1-year mortalities of 30.4% and
45.2%, respectively, in a mixed population dominated by
patients with haemato-oncological diseases, solid organ trans-
plantation, end-stage kidney disease or alcoholic liver cirrhosis.
In a review by van Hal et al., a mortality rate between 10% and
30% was reported in patients with S. aureus bacteraemia [14].
Recently, Pastagia et al. demonstrated a 90-day all-cause
mortality of 31.5% for 603 patients with MRSA bacteraemia
[15].
As expected, the most important aspect of MRSA treatment
in our study was timely identification of methicillin resistance.
MRSA is a rare bloodstream pathogen in Austrian patients [16]
and all patients who did not receive MRSA-active treatment
died from fulminant sepsis <72 h after the blood culture was
taken. In accordance with previous studies, increasing age was
an independent risk factor of early mortality [5,7,14,15]. In
addition, we identified pneumonia as independent positive
predictor of 28-day mortality in our study patients.
Vancomycin, which has been available for over 50 years [17],
was still used in our institution most frequently, in 50.8%
patients with MRSA bacteraemia. However, at least in univar-
iate analysis, vancomycin monotherapy was associated with
persistent MRSA bacteraemia  7 days. Most authors agree
that vancomycin has limitations such as low tissue penetration,
nephrotoxicity and increasing rates of treatment failure in
invasive MRSA infections [8]. During the observation period, in
vitro susceptibility testing against MRSA in our institution was
routinely performed using agar diffusion tests (standard Etest
on M€uller-Hinton agar or Etest detection of glycopeptide
resistance using a vancomycin–teicoplanin double-sided gradi-
ent test). According to Performance Standards for Antimicro-
bial Susceptibility Testing/CLSI or EUCAST clinical breakpoints,
all MRSA isolates were originally reported as susceptible to
vancomycin (data not shown). However, low level resistance to
vancomycin continues to evolve [7,18]. We therefore retro-
spectively assessed the in vitro susceptibility of MRSA blood
isolates using the broth microdilution reference method in
addition and detected reduced susceptibility to vancomycin,
defined as MIC of 2 mg/L, in 27.4% of MRSA isolates. One single
strain had a vancomycin MIC of 4 mg/L on re-testing, but had
been initially reported as susceptible by the standard Etest
method in 2002 because of the higher vancomycin breakpoint
of  4 mg/L in use at that time. Previously, Etest MIC of
1.5 mg/L or  2 mg/L appeared to be an important boundary
indicating imminent clinical failure [8] or increased mortality in
bloodstream infections, retrospectively [9]. However, similar
to the finding by Rojas et al. [19], we detected no relationship
between vancomycin MIC  2 mg/L determined in the broth
microdilution method and clinical or microbiological eradica-
tion failure. Nevertheless, we found a significant association
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FIG. 2. Cumulative survival curve of patients with methicillin-resis-
tant Staphylococcus aureus (MRSA) bacteraemia with and without
pneumonia during the follow-up period of 1 year shows that the
survival in the group of patients with pneumonia (n = 17) was worse
than in the group of patients without pneumonia (n = 107) (Log rank
significance test p 0.023).
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between vancomycin MIC and glycopeptide preteatment as
previously described by Lodise et al. [20].
Furthermore, the site of MRSA infection and source control
are crucial for clinical outcome. In the present study the
presence of endocarditis and the absence of high vancomycin
trough levels at steady state were significantly associated with
clinical and microbiological eradication failure. Although
vancomycin trough levels of 15–20 mg/L are recommended
worldwide to attain a vancomycin area under the curve/MIC
ratio  400 [21], only 22.6% of our patients receiving
vancomycin reached the targeted drug levels, possibly reflect-
ing low-level recommendations for a maximum trough level of
10.15 mg/L in 2000 and 14.5 mg/L in 2011 by the Department
of Laboratory Medicine at our institution.
Effective alternatives to vancomycin for treatment of
invasive MRSA infections are limited. The other glycopeptide
used as the second most common MRSA-active agent in the
present study was teicoplanin, for which sufficient trough
levels  20 mg/L were achieved in 85.7% of patients. How-
ever, for patients infected with isolates with reduced glyco-
peptide susceptibility, another class of antimicrobial substances
might be more appropriate [22]. Although all the MRSA
isolates tested were susceptible to linezolid and tigecycline,
only a small number of patients received one of these agents. A
limitation of the study was that we did not determine in vitro
susceptibility to daptomycin retrospectively. However, in our
institution daptomycin was only used as the initial MRSA
regimen in combination with fosfomycin in a single patient.
In conclusion, failure of clinical and microbiological eradica-
tion was associated with endocarditis and low vancomycin
trough levels, whereas vancomycinMIC values  2 mg/L had no
impact on treatment failure. There is therefore a strong need
for early diagnosis of MRSA bacteraemia, with identification of
the site of infection, optimization of vancomycin dosing,
appropriate use of vancomycin alternatives or combination
therapy, and optimal casemanagement including source control.
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TABLE 3. Patient demographics, recent major surgery, underlying diseases, comorbidities, source of bacteraemia, antimicrobial
treatment, vancomycin MIC and glycopeptide trough levels stratified for treatment outcome (failure versus success)
Characteristic
Treatment failure mean
(range) or n (%) (n = 50)
Treatment success mean
(range) or n (%) (n = 74)
p-value
(univariate)
p-value (multivariate); adjusted
odds ratio (95% CI)
Age (years) 66.6 (18–96) 59.4 (18–87) 0.031 –
Male sex 39 (78.0) 59 (79.7) ns –
Recent major surgery 25 (50.0) 45 (60.8) ns –
Underlying disease
Haemato-oncological disease 14 (28.0) 22 (29.7) ns –
Solid organ transplantation 5 (10.0) 9 (12.2) ns –
Alcoholic liver cirrhosis 8 (16.0) 6 (8.1) ns –
End-stage kidney disease 9 (18.0) 10 (13.5) ns –
Other 14 (28.0) 27 (36.5) ns –
Comorbidities
Diabetes mellitus 8 (16.0) 19 (25.7) ns –
Coronary artery disease 10 (20.0) 13 (17.6) ns –
COPD 6 (12.0) 11 (14.9) ns –
Source of bacteraemia
Infective endocarditis 9 (18.0) 2 (2.7) 0.014 0.027*; 13.3 (1.34–131.25)
Pneumonia 10 (20.0) 7 (9.5) 0.096 0.051; 2.2 (0.998–4.86)
Mediastinitis 0 (0) 3 (4.1) ns –
Peritonitis 2 (4.0) 2 (2.7) ns –
Wound infection 1 (2.0) 1 (1.4) ns –
Central venous catheter-related 10 (20.0) 27 (36.5) 0.056 –
Skin and soft tissue infection 1 (2.0) 4 (5.4) –
Foreign body infection 1 (2.0) 2 (2.7) ns –
Others 18 (36.0) 26 (35.1) ns –
ICU admission 44 (1–141) 58.4 (6–203) ns –
21 (42.0) 25 (33.8) ns –
Antimicrobial treatment
No MRSA active treatment 6 (12.0) 0 (0) 0.006 –
Any combination therapy 12 (24) 18 (24.3) ns –
Any glycopeptide 37 (74.0) 54 (73.0) ns –
Vancomycin 25 (50.0) 38 (51.4) ns –
Teicoplanin 12 (24.0) 16 (21.6) ns –
Linezolid 2 (4.0) 5 (6.8) ns –
Tigecycline 0 (0) 2 (2.7) ns –
Other antimicrobials 5 (10) 13 (17.6) ns
Vancomycin trough levels at steady state (mg/L) 13.3 (2.6–27.6) 18.6 (10.1–45.8) 0.016 0.016*; 0.29 (0.10–0.79)
Teicoplanin trough levels at steady state (mg/L) 39.6 (13.2–73.5) 48.9 (17–147) ns –
Surgical intervention 11 (22) 18 (24.3) ns –
Vancomycin MIC  2 mg/L by broth microdilution 16 (32) 19 (25.7) ns –
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.
ns = not significant in univariate logistic regression analysis (p-value  0.1).
*Statistically significant in multivariate logistic regression analysis, using stepwise backward method (p-value <0.05).
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